2-weekly docetaxel: issues for clinical practice

In the phase III trial comparing 2 docetaxel schedules (3-weekly versus 2-weekly) as first-line chemotherapy for CRPC, recently published in The Lancet Oncology, fewer serious adverse events, particularly hematologic toxicities, and longer times on treatment, in favor of the 2-weekly regimen are rep...

Full description

Saved in:
Bibliographic Details
Published inCancer biology & therapy Vol. 16; no. 1; pp. 17 - 18
Main Authors Massari, F, Maines, F, Bria, E, Galligioni, E, Caffo, O, Tortora, G
Format Journal Article
LanguageEnglish
Published United States Taylor & Francis 01.01.2015
Subjects
3-weekly schedule
Antineoplastic Agents - administration & dosage
doxetaxel
Drug Administration Schedule
Humans
Journal Clubs
Male
mCRPC
Prostatic Neoplasms, Castration-Resistant - drug therapy
Taxoids - administration & dosage
mCRPC
doxetaxel
3-weekly schedule
Online AccessGet full text

Cover

More Information
Summary:In the phase III trial comparing 2 docetaxel schedules (3-weekly versus 2-weekly) as first-line chemotherapy for CRPC, recently published in The Lancet Oncology, fewer serious adverse events, particularly hematologic toxicities, and longer times on treatment, in favor of the 2-weekly regimen are reported. 1,2,3
Bibliography:SourceType-Other Sources-1
ObjectType-News-1
content type line 66
ISSN:1538-4047
1555-8576
DOI:10.4161/15384047.2014.987534